Sign in Sign up for free

Affimed N.V Revenue Q/Q

What is the Revenue Q/Q of Affimed N.V?

The Revenue Q/Q of Affimed N.V. is -24.88%

What is the definition of Revenue Q/Q?

Quarterly revenue growth, year over year, is the increase of a company’s revenue compared to the performance in the corresponding quarter of a previous year expressed as a percentage.

quarterly growth yoy (year over year)

Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.

Revenue Q/Q of companies in the Health Care sector on NASDAQ compared to Affimed N.V

What does Affimed N.V do?

affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli

Companies with revenue q/q similar to Affimed N.V